Axcynsis Therapeutics Pte Ltd. has gained IND clearance from the FDA for AT03-65 for the treatment of patients with CLDN6-positive solid tumors. Axcynsis is planning to initiate a phase I trial in the ...

Context Therapeutics Inc. has announced the dosing of the first patient in its Phase 1 clinical trial for CTIM-76, a novel bispecific antibody targeting Claudin 6 (CLDN6) for the treatment of ...

GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell ...

CLDN6 is also one of the entry cofactors for ... CL6-H52P7) captured on an L1 Chip can bind to the Anti-Claudin-6 Antibody, Human IgG1, with an affinity constant of 57.8 pM, as determined by ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive gynaecologic and testicular cancers. The open-label trial aims to assess the ...

The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several ...

Image Credit: Sino Biological Inc. Loaded anti-GPRC5D antibody on Protein A Biosensor binds Human GPRC5D-Detergent Protein (His & FLAG Tag) with an affinity constant of 58.1 nM as determined in ...